TCS Positioned as a Leader in the IDC MarketScape for Worldwide Life Science R&D BPO Services

Tata Consultancy Services (TCS) (BSE: 532540, NSE: TCS), a leading global IT services, consulting and business solutions organization, has been positioned as a Leader in the IDC MarketScape for Worldwide Life Science R&D BPO Services.

According to the report, "TCS' broad portfolio; the company's end-to-end R&D IT and business services capabilities, including strategic consulting and cloud-based, platform-based solutions; its vast geographic footprint; and its years of experience in the life science industry, all make TCS a formidable option for companies seeking a preferred vendor to address their R&D ITO needs." It goes on to say that "TCS is focusing on an advisory-led transformation approach for higher digital adoption and value creation with a focus on IP-based digital health, real-world evidence, scientific collaboration, connected smart labs, data-driven development, digital clinical trials, automation, and regulatory intelligence."

"We leverage our deep contextual knowledge of the life sciences R&D value chain, cutting-edge R&D IT capabilities, investments in innovation around genomics and drug development, and expertise in AI / cognitive computing to help customers accelerate and scale up R&D programs which are core to their growth and transformation journeys," said Vikram Karakoti, Global Co-Head, Life Sciences, TCS. "This leadership position is a reflection of our strong vision, sustained investments in relevant capabilities, innovation efforts and the resultant market success."

TCS partners with leading life sciences companies to drive innovation and reimagine their R&D processes by leveraging next generation platforms and emerging technologies. The company offers a full set of services spanning consulting, cognitive business operations and digital transformation services, as well as platform solutions in the life sciences sector.

TCS' offerings span clinical project planning and budgeting, data anonymization, pharmacokinetic analysis and medical device support, content reuse in medical writing, development of e-consent related content forms, impact assessment for chemistry, manufacturing, and control (CMC), labeling and CMC authoring support, and development of digital content factory services for multi-channel marketing. Within pharmacovigilance, it has local safety officers who work with the respective qualified persons for pharmacovigilance to better support its customers.

At the core of its success as the preferred R&D partner for leading life sciences companies globally is TCS' deep domain knowledge and intellectual property around drug development. Its flagship offering, TCS ADD, is a cloud-native, cognitive platform that reimagines the end-to-end drug development value chain using digital technologies to enhance patient and user experience and improve clinical trial outcomes. The platform leverages the TCS Decision Fabric™ AI engine and spans across data standardization to safety and regulatory compliance.

Additionally, TCS leverages it Co-innovation Network that includes academia, government institutions, start-ups and technology providers to help customers further accelerate their innovation.

Shares of Tata Consultancy Services Ltd. was last trading in BSE at Rs. 3833.7 as compared to the previous close of Rs. 3771.1. The total number of shares traded during the day was 108583 in over 5849 trades.

The stock hit an intraday high of Rs. 3840 and intraday low of 3742.6. The net turnover during the day was Rs. 409428253.

Source : Equity Bulls

Keywords